We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

EGFR/HER2

EGFR and HER2 inhibitors act on two closely related receptor tyrosine kinases of the ErbB family. The epidermal growth factor receptor (EGFR, ErbB1) and human epidermal growth factor receptor 2 (HER2, ErbB2) form dimers with each other and with ErbB3 and ErbB4. Receptor activation engages the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways that control cell growth. Activating EGFR mutations in non-small-cell lung cancer have made the receptor a central model in kinase inhibitor research. Gefitinib and erlotinib are reversible EGFR inhibitors, and lapatinib inhibits both EGFR and HER2. Osimertinib binds covalently to EGFR carrying the T790M resistance mutation, and neratinib irreversibly inhibits HER2 and EGFR.

2 Items

  • SU 4313
    Cat. No.
    A22672
    CAS No.
    186611-55-2

    SU 4313

    SU-4313 is a small-molecule modulator of protein tyrosine kinases (PTKs). It inhibits multiple receptor tyrosine kinases with reported IC₅₀ values of 14.5 μM (PDGFR), 18.8 μM (FLK-1/VEGFR2), 11 μM (EGFR), 16.9 μM (HER2 kinase), and 8.0 μM (IGF-1R). Through its multi-kinase inhibitory profile, SU-4313 modulates tyrosine kinase–mediated signal transduction pathways involved in the regulation of cell proliferation and growth. It is therefore commonly used as a research tool for investigating aberrant receptor tyrosine kinase signaling and proliferation-associated pathways.  

    In stock View Details
    1 mg
    $30.00
    2 mg
    $45.00
    All 8 sizes
  • CHNQD-01281
    Cat. No.
    A28773
    CAS No.
    2762488-97-9

    CHNQD-01281

    CHNQD-01281 is an EGFR modulator that exhibits potent antiproliferative activity against cancer cells, with IC50 values of 0.079 and 0.081 μM for T24 and J82 cell lines, respectively. This compound effectively regulates both the EGFR/PI3K/AKT and EGFR/ERK signaling pathways, enhancing the chemotactic response of immune effector cells to chemokines. In vivo studies demonstrate that CHNQD-01281 significantly inhibits tumor growth in T24 xenograft mouse models and extends survival in MB49 allogeneic mouse models by promoting the infiltration of cytotoxic T cells.

    View Details

    Out of stock

    All 3 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...